Odysight.ai (ODYS) 10-Q 12 Aug 21 2021 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Jun. 30, 2021	Aug. 12, 2021
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Jun. 30, 2021
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2021
Current Fiscal Year End Date	--12-31
Entity File Number	333-188920
Entity Registrant Name	SCOUTCAM INC.
Entity Central Index Key	0001577445
Entity Tax Identification Number	47-4257143
Entity Incorporation, State or Country Code	NV
Entity Address, Address Line One	Suite 7A
Entity Address, Address Line Two	Industrial Park
Entity Address, Address Line Three	P.O. Box 3030
Entity Address, City or Town	Omer
Entity Address, Country	IL
Entity Address, Postal Zip Code	8496500
City Area Code	972
Local Phone Number	73 370-4691
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		6,928,527

Interim Condensed Consolidated

Interim Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 21,775	$ 3,373
Accounts receivable	60	17
Inventory	145	244
Medigus receivable		47
Other current assets	857	348
Total current assets	22,837	4,029
NON-CURRENT ASSETS:
Contract fulfillment assets	1,510	1,130
Property and equipment, net	400	269
Operating lease right-of-use assets	385	107
Severance pay asset	416	360
Total non-current assets	2,711	1,866
TOTAL ASSETS	25,548	5,895
CURRENT LIABILITIES:
Accounts payables	303	79
Contract liabilities		69
Operating lease liabilities - short term	187	60
Accrued compensation expenses	429	369
Medigus payable	13
Other accrued expenses	218	195
Total current liabilities	1,150	772
NON-CURRENT LIABILITIES:
Contract liabilities	1,385	779
Operating lease liabilities - long term	198	47
Liability for severance pay	333	333
Total non-current liabilities	1,916	1,159
TOTAL LIABILITIES	3,066	1,931
SHAREHOLDERS’ EQUITY:
Common stock, $0.001 par value; 300,000,000 and 75,000,000 shares authorized as of June 30, 2021 and December 31, 2020, 6,928,527 and 4,084,122 shares issued and outstanding as of June 30, 2021 and December 31, 2020, respectively	7	4
Additional paid-in capital	32,476	10,267
Accumulated deficit	(10,001)	(6,307)
TOTAL SHAREHOLDERS’ EQUITY	22,482	3,964
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY	$ 25,548	$ 5,895

Interim Condensed Consolidate_2

Interim Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2021	Dec. 31, 2020
Statement of Financial Position [Abstract]
Common Stock, Par or Stated Value Per Share		$ 0.001
Common Stock, Shares Authorized	300,000,000	75,000,000
Common stock, shares issued	6,928,527	4,084,122
Common stock, shares outstanding	6,928,527	4,084,122

Interim Condensed Consolidate_3

Interim Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Income Statement [Abstract]
Revenues	$ 274	$ 34	$ 298	$ 74
Cost of revenues	407	151	610	281
Gross Loss	(133)	(117)	(312)	(207)
Research and development expenses	421	115	754	370
Sales and marketing expenses	148	136	293	188
General and administrative expenses	1,395	568	2,328	1,680
Operating loss	(2,097)	(936)	(3,687)	(2,445)
Financing income (expenses), net	9	(34)	(7)	62
Net Loss	$ (2,088)	$ (970)	$ (3,694)	$ (2,383)
Net loss per ordinary share (basic and diluted, USD)	$ (0.31)	$ (0.28)	$ (0.67)	$ (0.73)
Weighted average ordinary shares (basic and diluted, in thousands)	6,724	3,431	5,480	3,243

Interim Condensed Consolidate_4

Interim Condensed Consolidated Statements of Changes in Shareholders' Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Total
Beginning balance, value at Dec. 31, 2019	$ 3	$ 4,159	$ (1,640)	$ 2,522
Beginning Balance, shares at Dec. 31, 2019	2,987
Issuance of shares and warrants	$ 1	2,857		2,858
Issuance of shares and warrants,shares	677
Stock based compensation		871		871
Conversion of a loan from Medigus		381		381
Conversion of a loan from Parent company, shares	87
Net loss			(2,383)	(2,383)
Ending balance, value at Jun. 30, 2020	$ 4	8,268	(4,023)	4,249
Ending Balance, shares at Jun. 30, 2020	3,751
Beginning balance, value at Mar. 31, 2020	$ 3	5,769	(3,053)	2,719
Beginning Balance, shares at Mar. 31, 2020	3,205
Issuance of shares and warrants	$ 1	1,948		1,949
Issuance of shares and warrants,shares	459
Stock based compensation		170		170
Conversion of a loan from Medigus		381		381
Conversion of a loan from Parent company, shares	87
Net loss			(970)	(970)
Ending balance, value at Jun. 30, 2020	$ 4	8,268	(4,023)	4,249
Ending Balance, shares at Jun. 30, 2020	3,751
Beginning balance, value at Dec. 31, 2020	$ 4	10,267	(6,307)	3,964
Beginning Balance, shares at Dec. 31, 2020	4,084
Issuance of shares and warrants	$ 2	19,116		19,118
Issuance of shares and warrants,shares	2,469
Stock based compensation		635		635
Exercise of warrants	$ 1	2,458		2,459
Exercise of warrants, shares	375
Net loss			(3,694)	(3,694)
Ending balance, value at Jun. 30, 2021	$ 7	32,476	(10,001)	22,482
Ending Balance, shares at Jun. 30, 2021	6,928
Beginning balance, value at Mar. 31, 2021	$ 7	30,242	(7,913)	22,336
Beginning Balance, shares at Mar. 31, 2021	6,699
Stock based compensation		556		556
Exercise of warrants		1,678		1,678
Exercise of warrants, shares	229
Net loss			(2,088)	(2,088)
Ending balance, value at Jun. 30, 2021	$ 7	$ 32,476	$ (10,001)	$ 22,482
Ending Balance, shares at Jun. 30, 2021	6,928

Interim Condensed Conolidated S

Interim Condensed Conolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (2,088)	$ (970)	$ (3,694)	$ (2,383)
Adjustments to reconcile net loss to net cash used in operations:
Depreciation	22	16	39	27
Other non-cash items	(56)	(25)	(56)	14
Share based compensation	556	155	635	837
Loss (Profit) from exchange differences on cash and cash equivalents	(16)	12	(4)	(84)
CHANGES IN OPERATING ASSET AND LIABILITY ITEMS:
Accounts receivables	(49)	(14)	(43)	(4)
Inventory	200	(177)	99	(302)
Medigus	14	(95)	60	(111)
Other current assets	(404)	(201)	(509)	(254)
Accounts payables	(189)	128	224	133
Contract fulfilment assets	(140)		(380)
Contract liabilities	(126)	126	537	170
Accrued compensation expenses	140	60	60	36
Other accrued expenses	(144)	(155)	(22)	(356)
Net cash flows used in operating activities	(2,280)	(1,140)	(3,054)	(2,277)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property and equipment	(53)	(36)	(170)	(221)
Net cash flows used in investing activities	(53)	(36)	(170)	(221)
CASH FLOWS FROM FINANCING ACTIVITIES:
Loan repayment to Medigus				(81)
Proceeds from exercise of warrants	1,723		2,504
Proceeds from issuance of shares and warrants	9,618	1,949	19,118	2,858
Net cash flows provided by financing activities	11,341	1,949	21,622	2,777
PROFIT (LOSS) FROM EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS	16	(12)	4	84
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS	9,024	761	18,402	363
BALANCE OF CASH AND CASH EQUIVALENTS AT THE BEGINNING OF THE PERIOD	12,751	2,847	3,373	3,245
BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF THE PERIOD	21,775	3,608	21,775	3,608
Non cash activities
Medigus loan settled against Medigus receivable				41
Conversion of a loan from Medigus		381		381
Issuance expenses	$ 45		$ 45

GENERAL

GENERAL	6 Months Ended
	Jun. 30, 2021
Organization, Consolidation and Presentation of Financial Statements [Abstract]
GENERAL	NOTE 1 – GENERAL a ScoutCam Inc. (the “Company”), formally known as Intellisense Solutions Inc. (Intellisense), was incorporated under the laws of the State of Nevada on March 22, 2013 . The Company was initially engaged in the business of developing web portals to allow companies and individuals to engage in the purchase and sale of vegetarian food products over the Internet. The Company was unable to execute it original business plan, develop significant operations or achieve commercial sales. Prior to the closing of the Securities Exchange Agreement (as defined below), the Company was a “shell company”. ScoutCam Ltd., or ScoutCam, was formed in the State of Israel on January 3, 2019 as a wholly-owned subsidiary of Medigus Ltd. (“Medigus”), an Israeli company traded on the Nasdaq Capital Market, and commenced operations on March 1, 2019. Upon incorporation, ScoutCam issued to Medigus 1,000,000 no 1,000,000 no ScoutCam was incorporated as part of a reorganization of Medigus, which was designed to distinguish ScoutCam’s miniaturized imaging business, or the micro ScoutCam™ portfolio, from Medigus’s other operations and to enable Medigus to form a separate business unit with dedicated resources focused on the promotion of such technology. In December 2019, Medigus and ScoutCam consummated a certain Amended and Restated Asset Transfer Agreement, under which Medigus transferred and assigned certain assets and intellectual property rights related to its miniaturized imaging business to ScoutCam. On September 16, 2019, Intellisense entered into a Securities Exchange Agreement (the “Exchange Agreement”), with Medigus, pursuant to which Medigus assigned, transferred and delivered 100% Although the transaction resulted in ScoutCam becoming a wholly owned subsidiary of Intellisense, the transaction constituted a reverse recapitalization since Medigus, the only shareholder of ScoutCam prior to the Exchange Agreement, was issued a substantial majority of the outstanding capital stock of Intellisense upon consummation of the Exchange Agreement, and also taking into account that prior to the Closing Date, Intellisense was considered as a shell corporation. Accordingly, ScoutCam is considered the accounting acquirer of the merged company. As of June 30, 2021 Medigus holds approximately 28% “Group” - the Company together with ScoutCam. ScoutCam has developed a range of micro CMOS (complementary metal-oxide semiconductor) and CCD (charge-coupled device) video cameras, including micro ScoutCam™ 1.2. These innovative cameras are suitable for both medical and industrial applications. Based on its proprietary technology, the Company designs and manufactures endoscopy and micro camera systems for partner companies. SCOUTCAM INC. NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 1 – GENERAL b. On August 9, 2021, the Company amended its Articles of Incorporation to effect a 9 to 1 reverse stock split As a result of the reverse stock split, every 9 shares of the Company’s outstanding Common Stock prior to the effect of that amendment was combined and reclassified into one share of the Company’s Common Stock. No fractional shares were issued in connection with or following the reverse split. The number of authorized capital of the Company’s Common Stock and par value of the shares remained unchanged. All share, stock option and per share information in these condensed consolidated financial statements have been adjusted to reflect the stock split on a retroactive basis. c . Since incorporation through June 30, 2021, the Group has an accumulated deficit of approximately $ 10 million and its activities have been funded mainly by its shareholders. The management believes the Group’s cash and cash resources as of June 30, 2021, will allow the Group to fund its operating plan through more than 12 months from the date of issuance of these financial statements. However, the Group expects to continue to incur significant research and development and other costs related to its ongoing operations and in order to continue its future operations, the Group will need to obtain additional funding until becoming profitable. d. In early 2020, the World Health Organization declared the rapidly spreading coronavirus disease (COVID-19) outbreak a pandemic. This pandemic has resulted in governments worldwide enacting emergency measures to combat the spread of the virus. The Group considered the impact of COVID-19 on its operations and determined that there were no material adverse impacts on the Group’s results of operations and financial position as of June 30, 2021. These estimates may change, as new events occur and additional information is obtained.

BASIS OF PRESENTATION AND SIGNI

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES	NOTE 2 – BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES A. Unaudited Interim Financial Statements The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Group’s Annual Report on Form 10-K for the year ended December 31, 2020. B. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation. C. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, inventory impairment, stock based compensation, as well as in estimates used in applying the revenue recognition policy. Actual results may differ from those estimates. D. Significant Accounting Policies The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements. E. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Group’s condensed consolidated financial statements. SCOUTCAM INC. NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

LEASES

LEASES	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
LEASES	NOTE 3 – LEASES ScoutCam leases office and vehicles under operating leases. On June 30, 2021, the Group’s ROU assets and lease liabilities for operating leases totaled $ 385 thousand. In December 2020, ScoutCam entered into a lease agreement for office space in Omer, Israel. The agreement is for 36 months beginning on January 1, 2021. ScoutCam holds the right to terminate the lease agreement after 24 months. In March 2021, ScoutCam entered into a lease agreement for additional office space in Omer, Israel. The agreement is until December 31, 2023. ScoutCam holds the right to terminate these agreements by December 31, 2022. Monthly lease payments under the agreements are approximately $ 12 thousand. Lease expenses recorded in the interim consolidated statements of operations were $ 49 thousand for the six months ended June 30, 2021. Supplemental cash flow information related to operating leases was as follows: SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES Six months ended USD in thousands Cash payments for operating leases 49 Total lease expenses 49 As of June 30, 2021, the Company’s operating leases had a weighted average remaining lease term of 1.52 years and a weighted average discount rate of 10 %. Future lease payments under operating leases as of June 30, 2021 were as follows: SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES Operating leases USD in thousands Remainder of 2021 100 2022 183 2023 149 Total future lease payments 432 Less imputed interest (47 ) Total lease liability balance 385 Total future lease payments 432 SCOUTCAM INC. NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

EQUITY

EQUITY	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
EQUITY	NOTE 4 – EQUITY Private placement: a. In December 2019, the Company allocated in a private issuance, a total of 379,269 units at a purchase price of USD $ 8.712 per unit. Each unit was comprised of two shares of common stock par value US$ 0.001 per share, one Warrant A (defined below) and two Warrants B (defined below). The immediate proceeds (gross) from the issuance of the units amounted to approximately USD 3.3 million. Each Warrant A was exercisable into one share of common stock of the Company at an exercise price of USD 5.355 per share during the 12 month period following the allocation. Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of USD 8.037 per share during the 18 month period following the allocation. In addition, Shrem Zilberman Group Ltd. (the “Consultant”) was entitled to receive the amount representing 3% of any exercise price of each Warrant A or Warrant B that may be exercised in the future. In the event the total proceeds received as a result of exercise of Warrants will be less than $ 2 million at the time of their expiration, the Consultant will be required to invest $ 250,000 in the Company in return for shares of common stock of Company. During 2020, 332,551 Warrants A were exercised. 46,718 unexercised Warrants A expired on December 30, 2020. During the second quarter of 2021, 185,271 Warrants B were exercised. 573,256 unexercised Warrants B expired on June 30, 2021. b. On March 3, 2020, the Company issued in a private issuance a total of 108,880 units at a purchase price of USD 8.712 per unit. Each unit was comprised of two shares of common stock par value US$ 0.001 Each Warrant A was exercisable into one share of common stock of the Company at an exercise price of USD 5.355 per share during the 12 month period following the allocation. Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of USD 8.037 per share during the 18 month period following the allocation. The gross proceeds from the issuance of all securities offered amounted to approximately USD 948 909 During 2021, all Warrants A were exercised. c. On May 18, 2020, the Company allocated in a private issuance a total of 229,569 units at a purchase price of USD 8.712 per unit. Each unit was comprised of two shares of common stock par value US$ 0.001 Each Warrant A is exercisable into one share of common stock of the Company at an exercise price of USD 5.355 per share during the 18 month period following the allocation. Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of USD 8.037 per share during the 24 month period following the allocation. SCOUTCAM INC. NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS The gross proceeds from the issuance of all securities offered amounted to approximately USD 2 1.9 During February 2021, 37,349 Warrants A were exercised. d. On June 23, 2020, (the “Conversion Date”), the Company entered into and consummated a Side Letter Agreement with Medigus, whereby the parties agreed to convert, at a conversion price of $ 4.356 , an outstanding line of credit previously extended by Medigus to the ScoutCam, which as of the Conversion Date was $ 381,136 , into (a) 87,497 shares of the Company’s common stock, (b) warrants to purchase 43,749 shares of common stock with an exercise price of $ 5.355 (Warrant A), and (c) warrants to purchase 87,497 shares of common stock with an exercise price of $ 8.037 (Warrant B). As the conversion price represented the same unit price as in the March 2020 and May 2020 private placements, no finance expenses have been recorded in statement of operations as a result of the conversion. Each Warrant A is exercisable into one share of common stock of the Company at an exercise price of USD 5.355 per share during the 12 months period following the allocation. Each Warrant B is exercisable into one share of common stock of the Company at an exercise price of USD 8.037 per share during the 18 months period following the allocation. During June 2021, all Warrants A were exercised. e. On March 22, 2021, the Company undertook to issue to certain investors (the “Investors”) 2,469,156 units (the “Units”) in exchange for an aggregate purchase price of $ 20 million. Each Unit consists of (i) one share of the Company’s common stock and (ii) one warrant to purchase one share of common stock with an exercise price of USD 10.35 per share (the “Warrant March 2021” and the “Exercise Price”). Each Warrant is exercisable until March 31, 2026 . Pursuant to the terms of the Warrant March 2021, following April 1, 2024, if the closing price of the common stock equals or exceeds 135% of the Exercise Price (subject to appropriate adjustments for stock splits, stock dividends, stock combinations and other similar transactions after the issue date of the Warrants) for any thirty (30) consecutive trading days, the Company may force the exercise of the Warrants, in whole or in part, by delivering to the Investors a notice of forced exercise. As of June 30, 2021, the Company had the following outstanding warrants to purchase common stock : SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK Warrant Issuance Date Expiration Date Exercise Price Per Share ($) Number of Shares of common stock Underlying Warrants Medigus Warrant December 30, 2019 December 30, 2022 - (*) 298,722 Warrant B March 3, 2020 September 3, 2021 8.037 217,727 Warrant A May 18, 2020 November 18, 2021 5.355 192,220 Warrant B May 18, 2020 May 18, 2022 8.037 459,137 Warrant B June 23, 2020 December 23, 2021 8.037 87,497 Warrant March 2021 March 29, 2021 March 31, 2026 10.350 2,469,156 3,724,459 (*) If ScoutCam achieves an aggregate amount of $33 million in sales within the first three years immediately after the Exchange Agreement, the Company will issue to Medigus 298,722 shares of the Company’s common stock, which represents 10 % of the Company’s issued and outstanding share capital as of the Exchange Agreement. SCOUTCAM INC. NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 4 – EQUITY Share-based compensation to employees, directors and service providers: In February 2020, the Company’s Board of Directors approved the 2020 Share Incentive Plan (the “Plan”). The Plan initially included a pool of 580,890 shares of common stock for grant to Company employees, consultants, directors and other service providers. On March 15, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional 64,099 shares of Common Stock. On June 22, 2020, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional 401,950 shares of common stock. During the second quarter of 2021, the Company’s Board of Directors approved an increase to the Company’s option pool pursuant to the Plan by an additional 777,778 shares of common stock. The Plan is designed to enable the Company to grant options to purchase ordinary shares and RSUs under various and different tax regimes including, without limitation: (i) pursuant and subject to Section 102 of the Israeli Tax Ordinance or any provision which may amend or replace it and any regulations, rules, orders or procedures promulgated thereunder and to designate them as either grants made through a trustee or not through a trustee; and (ii) pursuant and subject to Section 3(i) of the Israeli Tax Ordinance. During the six months ended June 30, 2021, the Company granted 567,687 options pursuant to the Plan. The fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option-pricing model, using the following assumptions: SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS Six months ended June 30, 2021 Underlying value of ordinary shares ($) 7.65 - 10.35 Exercise price ($) 2.61 - 7.20 Expected volatility (%) 45.80% - 47.44 % Term of the options (years) 7 Risk-free interest rate 0.78 1.33 % The cost of the benefit embodied in the options granted during the six months ended June 30, 2021, based on their fair value as at the grant date, is estimated to be approximately $ 3,784 thousands. These amounts will be recognized in statements of operations over the vesting period. SCOUTCAM INC. NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS NOTE 4 – EQUITY The following table summarizes stock option activity for the six months ended June 30, 2021: SCHEDULE OF STOCK OPTIONS ACTIVITY For the Six months ended June 30, 2021 Amount of options Weighted average exercise price $ Outstanding at beginning of period 737,049 2.61 Granted 567,687 4.09 Cancelled (87,934 ) 2.61 Outstanding at end of period 1,216,802 3.30 Vested at end of period 349,095 2.61 The following table sets forth the total share-based payment expenses resulting from options granted, included in the statements of operation: SCHEDULE OF TOTAL SHARE-BASED PAYMENT EXPENSES Six months ended June 30, 2021 USD in thousands Cost of revenues 9 Research and development 165 Sales and marketing 11 General and administrative 450 Total expenses 635 SCOUTCAM INC. NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

REVENUES

REVENUES	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
REVENUES	NOTE 5 – REVENUES Contract fulfillment assets and Contract liabilities: The Company’s contract fulfillment assets and contract liabilities as of June 30, 2021 and December 31, 2020 were as follows: SCHEDULE OF CONTRACT LIABILITIES June 30, December 31, 2021 2020 USD in thousands Contract fulfillment assets 1,510 1,130 Contract liabilities 1,385 848 Remaining Performance Obligations Remaining Performance Obligations (“RPO”) represents contracted revenue that has not yet been recognized, which includes deferred revenue and amounts that will be invoiced and recognized as revenue in future periods. As of June 30, 2021, the total RPO amounted to $ 2.7 million, which the Company expects to recognize over the expected manufacturing term of the product under development.

INVENTORY

INVENTORY	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
INVENTORY	NOTE 6 – INVENTORY Composed as follows: SCHEDULE OF INVENTORY June 30, December 31, 2021 2020 USD in thousands Raw materials and supplies 145 45 Finished goods - 278 Inventory write downs - (79 ) Inventory net 145 244 During the period ended June 30, 2021, no SCOUTCAM INC. NOTES TO THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

LOSS PER SHARE

LOSS PER SHARE	6 Months Ended
	Jun. 30, 2021
Earnings Per Share [Abstract]
LOSS PER SHARE	NOTE 7 – LOSS PER SHARE Basic loss per share is computed by dividing net loss attributable to ordinary shareholders of the Company, by the weighted average number of ordinary shares as described below. In computing the Company’s diluted loss per share, the numerator used in the basic loss per share computation is adjusted for the dilutive effect, if any, of the Company’s potential shares of common stock. The denominator for diluted loss per share is a computation of the weighted-average number of ordinary shares and the potential dilutive ordinary shares outstanding during the period.

RELATED PARTIES

RELATED PARTIES	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
RELATED PARTIES	NOTE 8 – RELATED PARTIES On May 30, 2019, ScoutCam Ltd. entered into an intercompany agreement with Medigus (the “Intercompany Agreement”) according to which ScoutCam Ltd. agreed to hire and retain certain services from Medigus. The agreed upon services provided under the Intercompany Agreement included: (1) lease of office space and clean room based on actual space utilized by ScoutCam Ltd. and in shared spaces according to employee ratio; (2) utilities such as electricity water, IT and communication services based on employee ratio; (3) car services, including car rental, gas usage, payment for toll roads based on 100% of expense incurred from a ScoutCam Ltd. employee car; (4) external accountant services at a price of USD 6,000 per annum; (5) directors and officers insurance at a sum of 1/3 of Medigus cost; (6) CFO services at a sum of 50% of Medigus company CFO employer cost; (7) every direct expense of ScoutCam Ltd. that is paid by Medigus in its entirety subject to approval of such direct expenses in advance; and (8) any other mutual expense that is borne by the parties according to the Respective portion of the Mutual Expense In addition, ScoutCam Ltd.’s employees provide support services to Medigus. On April 20, 2020, ScoutCam Ltd. entered into an amended and restated intercompany services agreement with Medigus. Balances with related parties SCHEDULE OF BALANCES WITH RELATED PARTIES June 30, 2021 December 31, 2020 Medigus receivable - 47 Medigus payable 13 -

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Jun. 30, 2021
Subsequent Events [Abstract]
SUBSEQUENT EVENTS	NOTE 9 – SUBSEQUENT EVENTS 1. On August 9, 2021, the Company amended its Articles of Incorporation to effect a 9 to 1 reverse stock split All share, stock option and per share information in these condensed consolidated financial statements have been adjusted to reflect the stock split on a retroactive basis. 2. On July 27, 2021, certain of the Company’s stockholders representing more than 50% of the Company’s outstanding share capital as of July 7, 2021 approved an additional amendment to the Company’s Articles of Incorporation (the “Staggered Board Certificate of Amendment”) in order to effect the implementation of a staggered board structure.

BASIS OF PRESENTATION AND SIG_2

BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES (Policies)	6 Months Ended
	Jun. 30, 2021
Accounting Policies [Abstract]
Unaudited Interim Financial Statements	A. Unaudited Interim Financial Statements The accompanying unaudited interim condensed financial statements have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) for interim financial information and with the instructions to Form 10-Q and Article 10 of U.S. Securities and Exchange Commission Regulation S-X. Accordingly, they do not include all the information and footnotes required by generally accepted accounting principles for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included (consisting only of normal recurring adjustments except as otherwise discussed). For further information, reference is made to the consolidated financial statements and footnotes thereto included in the Group’s Annual Report on Form 10-K for the year ended December 31, 2020.
Principles of Consolidation	B. Principles of Consolidation The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiary. All intercompany balances and transactions have been eliminated in consolidation.
Use of estimates	C. Use of estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates on an ongoing basis its assumptions, including those related to contingencies, deferred taxes, inventory impairment, stock based compensation, as well as in estimates used in applying the revenue recognition policy. Actual results may differ from those estimates.
Significant Accounting Policies	D. Significant Accounting Policies The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements.
Recent Accounting Pronouncements	E. Recent Accounting Pronouncements Management does not believe that any recently issued, but not yet effective, accounting standards, if currently adopted, would have a material effect on the Group’s condensed consolidated financial statements.

LEASES (Tables)

LEASES (Tables)	6 Months Ended
	Jun. 30, 2021
Leases [Abstract]
SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES	Supplemental cash flow information related to operating leases was as follows: SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES Six months ended USD in thousands Cash payments for operating leases 49 Total lease expenses 49
SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES	SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES Operating leases USD in thousands Remainder of 2021 100 2022 183 2023 149 Total future lease payments 432 Less imputed interest (47 ) Total lease liability balance 385 Total future lease payments 432

EQUITY (Tables)

EQUITY (Tables)	6 Months Ended
	Jun. 30, 2021
Equity [Abstract]
SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK	As of June 30, 2021, the Company had the following outstanding warrants to purchase common stock : SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK Warrant Issuance Date Expiration Date Exercise Price Per Share ($) Number of Shares of common stock Underlying Warrants Medigus Warrant December 30, 2019 December 30, 2022 - (*) 298,722 Warrant B March 3, 2020 September 3, 2021 8.037 217,727 Warrant A May 18, 2020 November 18, 2021 5.355 192,220 Warrant B May 18, 2020 May 18, 2022 8.037 459,137 Warrant B June 23, 2020 December 23, 2021 8.037 87,497 Warrant March 2021 March 29, 2021 March 31, 2026 10.350 2,469,156 3,724,459 (*) If ScoutCam achieves an aggregate amount of $33 million in sales within the first three years immediately after the Exchange Agreement, the Company will issue to Medigus 298,722 shares of the Company’s common stock, which represents 10 % of the Company’s issued and outstanding share capital as of the Exchange Agreement.
SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS	The fair value of each option was estimated as of the date of grant or reporting period using the Black-Scholes option-pricing model, using the following assumptions: SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS Six months ended June 30, 2021 Underlying value of ordinary shares ($) 7.65 - 10.35 Exercise price ($) 2.61 - 7.20 Expected volatility (%) 45.80% - 47.44 % Term of the options (years) 7 Risk-free interest rate 0.78 1.33 %
SCHEDULE OF STOCK OPTIONS ACTIVITY	The following table summarizes stock option activity for the six months ended June 30, 2021: SCHEDULE OF STOCK OPTIONS ACTIVITY For the Six months ended June 30, 2021 Amount of options Weighted average exercise price $ Outstanding at beginning of period 737,049 2.61 Granted 567,687 4.09 Cancelled (87,934 ) 2.61 Outstanding at end of period 1,216,802 3.30 Vested at end of period 349,095 2.61
SCHEDULE OF TOTAL SHARE-BASED PAYMENT EXPENSES	The following table sets forth the total share-based payment expenses resulting from options granted, included in the statements of operation: SCHEDULE OF TOTAL SHARE-BASED PAYMENT EXPENSES Six months ended June 30, 2021 USD in thousands Cost of revenues 9 Research and development 165 Sales and marketing 11 General and administrative 450 Total expenses 635

REVENUES (Tables)

REVENUES (Tables)	6 Months Ended
	Jun. 30, 2021
Revenue from Contract with Customer [Abstract]
SCHEDULE OF CONTRACT LIABILITIES	The Company’s contract fulfillment assets and contract liabilities as of June 30, 2021 and December 31, 2020 were as follows: SCHEDULE OF CONTRACT LIABILITIES June 30, December 31, 2021 2020 USD in thousands Contract fulfillment assets 1,510 1,130 Contract liabilities 1,385 848

INVENTORY (Tables)

INVENTORY (Tables)	6 Months Ended
	Jun. 30, 2021
Inventory Disclosure [Abstract]
SCHEDULE OF INVENTORY	Composed as follows: SCHEDULE OF INVENTORY June 30, December 31, 2021 2020 USD in thousands Raw materials and supplies 145 45 Finished goods - 278 Inventory write downs - (79 ) Inventory net 145 244

RELATED PARTIES (Tables)

RELATED PARTIES (Tables)	6 Months Ended
	Jun. 30, 2021
Related Party Transactions [Abstract]
SCHEDULE OF BALANCES WITH RELATED PARTIES	Balances with related parties SCHEDULE OF BALANCES WITH RELATED PARTIES June 30, 2021 December 31, 2020 Medigus receivable - 47 Medigus payable 13 -

GENERAL (Details Narrative)

GENERAL (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands	Aug. 09, 2021	Sep. 16, 2019	Jun. 30, 2021	Dec. 31, 2020	Mar. 31, 2019	Jan. 03, 2019
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Entity Incorporation, State or Country Code			NV
Entity Incorporation, Date of Incorporation			Mar. 22, 2013
Common stock, shares issued			6,928,527	4,084,122
Retained Earnings (Accumulated Deficit)			$ 10,001	$ 6,307
Subsequent Event [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Reverse stock split	9 to 1 reverse stock split
Securities Exchange Agreement [Member] | Medigus [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Noncontrolling Interest, Ownership Percentage by Parent			28.00%
Medigus Ltd [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Common stock, shares issued					1,000,000	1,000,000
Common stock, par value					$ 0	$ 0
ScoutCam Ltd., [Member] | Securities Exchange Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Exchange agreement description		On September 16, 2019, Intellisense entered into a Securities Exchange Agreement (the “Exchange Agreement”), with Medigus, pursuant to which Medigus assigned, transferred and delivered 100% of its holdings in ScoutCam to Intellisense, in exchange for consideration consisting of shares of Intellisense’s common stock representing 60% of the issued and outstanding share capital of Intellisense immediately upon the closing of the Exchange Agreement (the “Closing”).
Equity ownership percentage		100.00%

SCHEDULE OF SUPPLEMENTAL CASH F

SCHEDULE OF SUPPLEMENTAL CASH FLOW INFORMATION RELATED TO OPERATING LEASES (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Leases [Abstract]
Cash payments for operating leases	$ 49
Total lease expenses	$ 49

SCHEDULE OF MATURITIES LEASE LI

SCHEDULE OF MATURITIES LEASE LIABILITIES UNDER OPERATING LEASES (Details) $ in Thousands	Jun. 30, 2021USD ($)
Leases [Abstract]
Remainder of 2021	$ 100
2022	183
2023	149
Total future lease payments	432
Less imputed interest	(47)
Total lease liability balance	$ 385

LEASES (Details Narrative)

LEASES (Details Narrative) - USD ($) $ in Thousands	Jan. 02, 2021	Jun. 30, 2021	Dec. 31, 2020
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Operating Lease, Right-of-Use Asset		$ 385	$ 107
Operating Lease, Payments		49
Operating Lease, Expense		$ 49
Operating Lease, Weighted Average Remaining Lease Term		1 year 6 months 7 days
Operating Lease, Weighted Average Discount Rate, Percent		10.00%
Lease Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Lessee, Operating Lease, Description		In December 2020, ScoutCam entered into a lease agreement for office space in Omer, Israel. The agreement is for 36 months beginning on January 1, 2021. ScoutCam holds the right to terminate the lease agreement after 24 months. In March 2021, ScoutCam entered into a lease agreement for additional office space in Omer, Israel. The agreement is until December 31, 2023. ScoutCam holds the right to terminate these agreements by December 31, 2022. Monthly lease payments under the agreements are approximately $
Operating Lease, Payments	$ 12
Operating Lease, Expense		$ 49

SCHEDULE OF STOCK WARRANTS OUTS

SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK (Details) - $ / shares		6 Months Ended
		Jun. 30, 2021	Mar. 03, 2020
Medigus Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, Issuance Date		Dec. 30, 2019
Warrant, Expiration Date		Dec. 30, 2022
Warrant, Exercise Price Per Share	[1]
Warrant, Number of Shares of Common Stock Underlying Warrants		298,722
Warrant B [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, Issuance Date		Mar. 3, 2020
Warrant, Expiration Date		Sep. 3, 2021
Warrant, Exercise Price Per Share		$ 8.037	$ 8.037
Warrant, Number of Shares of Common Stock Underlying Warrants		217,727
Warrant A [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, Issuance Date		May 18, 2020
Warrant, Expiration Date		Nov. 18, 2021
Warrant, Exercise Price Per Share		$ 5.355	$ 5.355
Warrant, Number of Shares of Common Stock Underlying Warrants		192,220
Warrant B One [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, Issuance Date		May 18, 2020
Warrant, Expiration Date		May 18, 2022
Warrant, Exercise Price Per Share		$ 8.037
Warrant, Number of Shares of Common Stock Underlying Warrants		459,137
Warrant B Two [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, Issuance Date		Jun. 23, 2020
Warrant, Expiration Date		Dec. 23, 2021
Warrant, Exercise Price Per Share		$ 8.037
Warrant, Number of Shares of Common Stock Underlying Warrants		87,497
Warrant March 2021 [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, Issuance Date		Mar. 29, 2021
Warrant, Expiration Date		Mar. 31, 2026
Warrant, Exercise Price Per Share		$ 10.350
Warrant, Number of Shares of Common Stock Underlying Warrants		2,469,156
Warrant [Member]
Accumulated Other Comprehensive Income (Loss) [Line Items]
Warrant, Number of Shares of Common Stock Underlying Warrants		3,724,459
[1]	If ScoutCam achieves an aggregate amount of $33 million in sales within the first three years immediately after the Exchange Agreement, the Company will issue to Medigus 298,722 shares of the Company’s common stock, which represents 10 % of the Company’s issued and outstanding share capital as of the Exchange Agreement.

SCHEDULE OF STOCK WARRANTS OU_2

SCHEDULE OF STOCK WARRANTS OUTSTANDING TO PURCHASE COMMON STOCK (Details) (Parenthetical)	6 Months Ended
	Jun. 30, 2021shares
Entity Listings [Line Items]
Expected sales period	3 years
Medigus Ltd [Member] | Exchange Agreement [Member]
Entity Listings [Line Items]
Class of Warrant or Right, Number of Securities Called by Warrants or Rights	298,722
Outstanding share capital percentage	10.00%

SCHEDULE OF SHARE-BASED PAYMENT

SCHEDULE OF SHARE-BASED PAYMENT AWARD, STOCK OPTIONS, VALUATION ASSUMPTIONS (Details)	6 Months Ended
	Jun. 30, 2021$ / shares
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Term of the options (years)	7 years
Minimum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Share Price	$ 7.65
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 2.61
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	45.80%
Risk-free interest rate	0.78%
Maximum [Member]
SEC Schedule, 12-18, Supplemental Information, Property-Casualty Insurance Underwriters [Line Items]
Share Price	$ 10.35
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Exercise Price	$ 7.20
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	47.44%
Risk-free interest rate	1.33%

SCHEDULE OF STOCK OPTIONS ACTIV

SCHEDULE OF STOCK OPTIONS ACTIVITY (Details)	6 Months Ended
	Jun. 30, 2021$ / sharesshares
Equity [Abstract]
Options, Outstanding at beginning of period | shares	737,049
Weighted average exercise price, Outstanding at beginning of period | $ / shares	$ 2.61
Options, Granted | shares	567,687
Weighted average exercise price, Granted | $ / shares	$ 4.09
Options, Cancelled | shares	(87,934)
Weighted average exercise price, Cancelled | $ / shares	$ 2.61
Options, Outstanding at end of period | shares	1,216,802
Weighted average exercise price, Outstanding at end of period | $ / shares	$ 3.30
Options, Vested at end of period | shares	349,095
Weighted average exercise price, Vested at end of period | $ / shares	$ 2.61

SCHEDULE OF TOTAL SHARE-BASED P

SCHEDULE OF TOTAL SHARE-BASED PAYMENT EXPENSES (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Total expenses	$ 556	$ 155	$ 635	$ 837
Cost of Sales [Member]
Total expenses			9
Research and Development Expense [Member]
Total expenses			165
Selling and Marketing Expense [Member]
Total expenses			11
General and Administrative Expense [Member]
Total expenses			$ 450

EQUITY (Details Narrative)

EQUITY (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands

Mar. 22, 2021

Jun. 23, 2020

Jun. 22, 2020

May 18, 2020

Mar. 15, 2020

Mar. 03, 2020

Feb. 28, 2021

Feb. 29, 2020

Dec. 31, 2019

Jun. 30, 2021

Jun. 30, 2020

Jun. 30, 2021

Jun. 30, 2020

Dec. 31, 2020

Dec. 30, 2020

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, New Issues

379,269

Shares Issued, Price Per Share

$ 8.712

Number of common stock

2

Common stock par value

$ 0.001

$ 0.001

Proceeds from issuance of common stock

$ 3,300

Proceeds from Warrant Exercises

$ 1,723

$ 2,504

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

567,687

2020 Share Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

567,687

Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value

$ 3,784

Letter Agreement [Member] | Medigus Ltd [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Debt Instrument, Convertible, Conversion Price

$ 4.356

Consultant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrant exercise price percentage

3.00%

Proceeds from Warrant Exercises

$ 2,000

Stock Issued During Period, Value, New Issues

$ 250,000

Investors [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, New Issues

2,469,156

Proceeds from issuance of common stock

$ 20,000

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 10.35

Warrants and Rights Outstanding, Maturity Date

Mar. 31, 2026

Warrants description

Pursuant to the terms of the Warrant March 2021, following April 1, 2024, if the closing price of the common stock equals or exceeds 135% of the Exercise Price (subject to appropriate adjustments for stock splits, stock dividends, stock combinations and other similar transactions after the issue date of the Warrants) for any thirty (30) consecutive trading days, the Company may force the exercise of the Warrants, in whole or in part, by delivering to the Investors a notice of forced exercise.

Employees, Consultants, Directors and Other Service Providers [Member] | 2020 Share Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

580,890

Board of Directors [Member] | 2020 Share Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross

401,950

64,099

777,778

Each Warrant A [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

1

1

1

1

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.355

$ 5.355

$ 5.355

$ 5.355

Warrants and Rights Outstanding, Term

12 months

18 months

12 months

12 months

Number of share warrants exercised

332,551

Class of Warrant or Right, Outstanding

46,718

Each Warrant B [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

1

1

1

1

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 8.037

$ 8.037

$ 8.037

$ 8.037

Warrants and Rights Outstanding, Term

18 months

24 months

18 months

18 months

Number of share warrants exercised

185,271

Class of Warrant or Right, Outstanding

573,256

573,256

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Shares, New Issues

229,569

108,880

Shares Issued, Price Per Share

$ 8.712

$ 8.712

Common stock par value

$ 0.001

$ 0.001

Proceeds from issuance of common stock

$ 2,000

$ 948

Proceeds from issuance of shares net of issuance expense

$ 1,900

$ 909

Warrant A [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

1

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.355

$ 5.355

$ 5.355

Warrants and Rights Outstanding, Term

12 months

Number of share warrants exercised

37,349

Warrants and Rights Outstanding, Maturity Date

Nov. 18, 2021

Nov. 18, 2021

Warrant A [Member] | Letter Agreement [Member] | Medigus Ltd [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

43,749

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 5.355

Warrant B [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

1

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 8.037

$ 8.037

$ 8.037

Warrants and Rights Outstanding, Term

18 months

Warrants and Rights Outstanding, Maturity Date

Sep. 3, 2021

Sep. 3, 2021

Warrant B [Member] | Letter Agreement [Member] | Medigus Ltd [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Class of Warrant or Right, Number of Securities Called by Each Warrant or Right

87,497

Class of Warrant or Right, Exercise Price of Warrants or Rights

$ 8.037

Common Stock [Member] | Letter Agreement [Member] | Medigus Ltd [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock Issued During Period, Value, Conversion of Convertible Securities

$ 381,136

Stock Issued During Period, Shares, Conversion of Convertible Securities

87,497

SCHEDULE OF CONTRACT LIABILITIE

SCHEDULE OF CONTRACT LIABILITIES (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Revenue from Contract with Customer [Abstract]
Contract fulfillment assets	$ 1,510	$ 1,130
Contract liabilities	$ 1,385	$ 848

REVENUES (Details Narrative)

REVENUES (Details Narrative) $ in Millions	Jun. 30, 2021USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, Remaining Performance Obligation, Amount	$ 2.7

SCHEDULE OF INVENTORY (Details)

SCHEDULE OF INVENTORY (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials and supplies	$ 145	$ 45
Finished goods		278
Inventory write downs		(79)
Inventory net	$ 145	$ 244

INVENTORY (Details Narrative)

INVENTORY (Details Narrative) $ in Thousands	6 Months Ended
	Jun. 30, 2021USD ($)
Inventory Disclosure [Abstract]
Impairment occurred	$ 0

SCHEDULE OF BALANCES WITH RELAT

SCHEDULE OF BALANCES WITH RELATED PARTIES (Details) - USD ($) $ in Thousands	Jun. 30, 2021	Dec. 31, 2020
Related Party Transactions [Abstract]
Medigus receivable		$ 47
Medigus payable	$ 13

RELATED PARTIES (Details Narrat

RELATED PARTIES (Details Narrative) - Medigus Ltd [Member] - USD ($) $ in Thousands	Apr. 20, 2020	May 30, 2019
Intercompany Agreement [Member]
Entity Listings [Line Items]
Intercompany agreement description		The agreed upon services provided under the Intercompany Agreement included: (1) lease of office space and clean room based on actual space utilized by ScoutCam Ltd. and in shared spaces according to employee ratio; (2) utilities such as electricity water, IT and communication services based on employee ratio; (3) car services, including car rental, gas usage, payment for toll roads based on 100% of expense incurred from a ScoutCam Ltd. employee car; (4) external accountant services at a price of USD
External accountant service price		$ 6,000
Amended and Restated Intercompany Services Agreement [Member]
Entity Listings [Line Items]
Intercompany agreement description	ScoutCam Ltd. entered into an amended and restated intercompany services agreement with Medigus.

SUBSEQUENT EVENTS (Details Narr

SUBSEQUENT EVENTS (Details Narrative)	Aug. 09, 2021
Subsequent Event [Member]
Subsequent Event [Line Items]
Reverse stock split	9 to 1 reverse stock split